Daiichi Sankyo Inc Drug Patent Portfolio
Daiichi Sankyo Inc owns 3 orange book drugs protected by 25 US patents Given below is the list of Daiichi Sankyo Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10435404 | Formulations of a compound modulating kinases | 24 Jul, 2038 | Active |
| US10941142 | Formulations of a compound modulating kinases | 24 Jul, 2038 | Active |
| US10961240 | Formulations of a compound modulating kinases | 24 Jul, 2038 | Active |
| US10189833 | Solid forms of a compound modulating kinases | 05 May, 2036 | Active |
| US10730876 | Synthesis of a compound that modulates kinases | 05 May, 2036 | Active |
| US9802932 | Solid forms of a compound modulating kinases | 05 May, 2036 | Active |
| US9675549 | Tablet containing composite with cyclodextrin | 30 Sep, 2033 | Active |
| US9358235 | Kinase modulation, and indications therefor | 08 Jun, 2033 | Active |
| US7893075 | Compounds modulating c-fms and/or c-kit activity and uses therefor | 04 May, 2033 | Active |
| US8357690 | Methods of treatment using combination therapy | 26 Feb, 2031 | Active |
| US9555040 | Methods of treating proliferative diseases | 14 May, 2030 | Active |
| US8836218 | Methods of treatment using combination therapy | 23 Mar, 2030 | Active |
| US7968543 | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease | 15 Aug, 2029 | Active |
| US8865710 | Methods of treating proliferative diseases | 15 Aug, 2029 | Active |
| US7820657 | Imidazolothiazole compounds for the treatment of disease | 26 Sep, 2028 | Active |
| US8461169 | Compounds modulating c-fms and/or c-kit activity | 19 Apr, 2028 | Active |
| US9149532 | Pharmaceutical composition | 28 Mar, 2028 | Active |
| US8404700 | Compounds modulating c-fms and/or c-kit activity and uses therefor | 21 Nov, 2027 | Active |
| US8722702 | Compounds modulating c-fms and/or c-kit activity and uses therefor | 21 Nov, 2027 | Active |
| US9169250 | Compounds modulating c-fms and/or c-kit activity and uses therefor | 21 Nov, 2027 | Active |
| US7365205 | Diamine derivatives | 18 Apr, 2027 | Active |
| US8129374 | Method of using imidazolothiazole compounds for the treatment of disease | 16 Mar, 2027 | Active |
| US8557810 | Imidazolothiazole compounds for the treatment of disease | 16 Mar, 2027 | Active |
| US8883783 | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith | 16 Mar, 2027 | Active |
| US9585892 | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith | 16 Mar, 2027 | Active |
Latest Legal Activities on Daiichi Sankyo Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Daiichi Sankyo Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jul, 2024 | US9555040 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jul, 2024 | US8357690 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Feb, 2024 | US10730876 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US8557810 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US8129374 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US8836218 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US8357690 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US7820657 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US7820657 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US8129374 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US8357690 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US8557810 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US8836218 |
| Initial letter Re: PTE Application to regulating agency | 02 Oct, 2023 | US7820657 |
| Initial letter Re: PTE Application to regulating agency | 02 Oct, 2023 | US8557810 |
Daiichi Sankyo Inc Drug Patents' Oppositions Filed in EPO
Daiichi Sankyo Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 01, 2013, by Generics [Uk] Limited. This opposition was filed on patent number EP02743653A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08720658A | May, 2018 | Hexal AG | Granted and Under Opposition |
| EP08720658A | May, 2018 | Generics [UK] Ltd | Granted and Under Opposition |
| EP02743653A | May, 2013 | Generics [UK] Limited | Opposition rejected |
Daiichi Sankyo Inc's Family Patents
Daiichi Sankyo Inc drugs have patent protection in a total of 45 countries. It's US patent count contributes only to 20.7% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Daiichi Sankyo Inc Drug List
Given below is the complete list of Daiichi Sankyo Inc's drugs and the patents protecting them.
1. Savaysa
Savaysa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9149532 | Pharmaceutical composition |
28 Mar, 2028
(2 years from now)
| Active |
| US7365205 | Diamine derivatives |
18 Apr, 2027
(1 year, 9 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Savaysa's drug page
2. Turalio
Turalio is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10435404 | Formulations of a compound modulating kinases |
24 Jul, 2038
(13 years from now)
| Active |
| US10941142 | Formulations of a compound modulating kinases |
24 Jul, 2038
(13 years from now)
| Active |
| US10961240 | Formulations of a compound modulating kinases |
24 Jul, 2038
(13 years from now)
| Active |
| US10189833 | Solid forms of a compound modulating kinases |
05 May, 2036
(10 years from now)
| Active |
| US10730876 | Synthesis of a compound that modulates kinases |
05 May, 2036
(10 years from now)
| Active |
| US9802932 | Solid forms of a compound modulating kinases |
05 May, 2036
(10 years from now)
| Active |
| US9358235 | Kinase modulation, and indications therefor |
08 Jun, 2033
(7 years from now)
| Active |
| US7893075 | Compounds modulating c-fms and/or c-kit activity and uses therefor |
04 May, 2033
(7 years from now)
| Active |
| US8461169 | Compounds modulating c-fms and/or c-kit activity |
19 Apr, 2028
(2 years from now)
| Active |
| US8404700 | Compounds modulating c-fms and/or c-kit activity and uses therefor |
21 Nov, 2027
(2 years from now)
| Active |
| US8722702 | Compounds modulating c-fms and/or c-kit activity and uses therefor |
21 Nov, 2027
(2 years from now)
| Active |
| US9169250 | Compounds modulating c-fms and/or c-kit activity and uses therefor |
21 Nov, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Turalio's drug page
3. Vanflyta
Vanflyta is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9675549 | Tablet containing composite with cyclodextrin |
30 Sep, 2033
(8 years from now)
| Active |
| US8357690 | Methods of treatment using combination therapy |
26 Feb, 2031
(5 years from now)
| Active |
| US9555040 | Methods of treating proliferative diseases |
14 May, 2030
(4 years from now)
| Active |
| US8836218 | Methods of treatment using combination therapy |
23 Mar, 2030
(4 years from now)
| Active |
| US7968543 | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
15 Aug, 2029
(4 years from now)
| Active |
| US8865710 | Methods of treating proliferative diseases |
15 Aug, 2029
(4 years from now)
| Active |
| US7820657 | Imidazolothiazole compounds for the treatment of disease |
26 Sep, 2028
(3 years from now)
| Active |
| US8129374 | Method of using imidazolothiazole compounds for the treatment of disease |
16 Mar, 2027
(1 year, 8 months from now)
| Active |
| US8557810 | Imidazolothiazole compounds for the treatment of disease |
16 Mar, 2027
(1 year, 8 months from now)
| Active |
| US8883783 | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
16 Mar, 2027
(1 year, 8 months from now)
| Active |
| US9585892 | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
16 Mar, 2027
(1 year, 8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vanflyta's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List